Explosive growth in biotechnology in recent years can't be understated. What's fueling this rapid growth varies, as biotech's applications range from healthcare and agriculture to energy. COVID-19 brought more attention to biotechnology, as biotech companies were central to vaccine development and reopening the economy. Biotech's potential to develop vaccines shifted the industry's trajectory, with investment reaching unprecedented levels globally and spurring more start-up activity than ever. Sky-high investment began settling in 2022, as higher interest rates moved risk-averse investors away from early-stage companies into established companies with a higher likelihood of return. Investor uncertainty continued into 2023, with high interest rates, stubborn inflation and bank failures stoking anxieties. Still, even as investment activity settles, revenue has been expanding at a CAGR of 0.8% to an estimated $477.1 billion over the past five years, including expected growth of 2.1% in 2023.
Companies in the Global Biotechnology industry primarily use living organisms or molecular and cellular techniques to develop products that are used in agriculture, food, industrial and medicine production.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry's key players and their market shares.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- F. Hoffmann-La Roche AG
- Gilead Sciences Inc.
- Johnson & Johnson
- Novartis AG
- Merck & Co. Inc.
- Amgen Inc.
Methodology
LOADING...